To further characterize the association between KMT2A gene rearrangement and BRAF mutations, we conducted a retrospective review of our HopeSeq Heme panel database and identified 77 AML patients with the KMT2A gene rearrangement. This evidence concerns the gene BRAF and acute myeloid leukemia.